Zacks Investment Research upgraded shares of OpGen Inc (NASDAQ:OPGN) from a sell rating to a hold rating in a report released on Wednesday.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

Separately, Rodman & Renshaw set a $3.30 price target on shares of OpGen and gave the stock a buy rating in a report on Wednesday, August 10th.

Shares of OpGen (NASDAQ:OPGN) opened at 1.41 on Wednesday. The stock has a 50 day moving average of $1.63 and a 200-day moving average of $1.61. OpGen has a 12 month low of $1.02 and a 12 month high of $4.65. The company’s market cap is $30.55 million.

OpGen (NASDAQ:OPGN) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.09. On average, analysts forecast that OpGen will post ($1.17) EPS for the current year.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

5 Day Chart for NASDAQ:OPGN

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for OpGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc and related companies with's FREE daily email newsletter.